But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
